. 2007 Apr 3;96(8):1183–1190. doi: 10.1038/sj.bjc.6603719

Table 4. Study included in comparison of 5FU-based chemoradiation, followed by chemotherapy vs another chemotherapy agent-based chemoradiation, followed by chemotherapy.

Authors	Group (number randomised)	Median age and gender	Chemotherapy/radio-therapy used and dose
Wilkowski et al (2006)	5FU chemoradiotherapy (n=32)	NA	5FU 350 mg m⁻² irradiation day⁻¹+50 Gy conventional radiation
	Gemcitabine+cisplatin chemoradiotherapy (n=33)	NA	Gemcitabine 300 mg m⁻² day⁻¹ 30 min infusion, cisplatin 30 mg m⁻² day⁻¹ 60 min infusion on days 1, 8, 22 and 29+50 Gy conventional radiation
Li et al (2003)	5FU chemoradiotherapy (n=16)	69 years; 12 men, 4 women	500 mgm⁻² day⁻¹ for 3 days, repeated every 2 weeks for 6 weeks+3D conformal radiotherapy 50.4–61.2 Gy
	Gemcitabine chemoradiotherapy (n=18)	68.5 years; 13 men, 5 women	600 mg m⁻² week⁻¹ for 6 weeks+3D conformal radiotherapy 50.4–61.2 Gy
GITSG (1985)	5FU chemoradiotherapy (n=79)		5FU 500 mg m⁻² on first 3 days of each radiotherapy course+6000 rad double split course, followed by weekly maintenance with 5FU 500 mg m⁻² till progression
	Adriamycin chemoradiotherapy (n=78)		Adriamycin 15 mg m⁻² on day 1; thereafter 10 mg m⁻² week⁻¹, for a minimum of five doses+4000 rad continuous course, followed by weekly maintenance with 5FU 500 mg m⁻² till progression

FU=fluorouracil.